Gupta J, Singh K, Bhatt A, Porwal P, Rani R, Dubey A
3 Biotech. 2024; 14(11):260.
PMID: 39376479
PMC: 11456089.
DOI: 10.1007/s13205-024-04104-5.
Yi F, Traynelis S, Hansen K
Methods Mol Biol. 2024; 2799:55-77.
PMID: 38727903
PMC: 11311247.
DOI: 10.1007/978-1-0716-3830-9_5.
Ritter N, Disse P, Aymanns I, Mucher L, Schreiber J, Brenker C
Mol Neurobiol. 2023; 60(12):7238-7252.
PMID: 37542648
PMC: 10657792.
DOI: 10.1007/s12035-023-03526-1.
Ritter N, Disse P, Wunsch B, Seebohm G, Strutz-Seebohm N
Biomedicines. 2023; 11(5).
PMID: 37239037
PMC: 10216354.
DOI: 10.3390/biomedicines11051367.
Harris L, Regan M, Myers S, Nocilla K, Akins N, Tahirovic Y
ACS Chem Neurosci. 2023; 14(5):917-935.
PMID: 36779874
PMC: 9983021.
DOI: 10.1021/acschemneuro.2c00779.
Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor.
Zaczek R, Traynelis S, Dingledine R, Koszalka G, Laskowitz D
Clin Pharmacol Drug Dev. 2023; 12(7):706-717.
PMID: 36642931
PMC: 10329973.
DOI: 10.1002/cpdd.1217.
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.
Hansen K, Wollmuth L, Bowie D, Furukawa H, Menniti F, Sobolevsky A
Pharmacol Rev. 2021; 73(4):298-487.
PMID: 34753794
PMC: 8626789.
DOI: 10.1124/pharmrev.120.000131.
Allosteric antagonist action at triheteromeric NMDA receptors.
Gibb A
Neuropharmacology. 2021; 202:108861.
PMID: 34736958
PMC: 8641061.
DOI: 10.1016/j.neuropharm.2021.108861.
A Glutamate -Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use.
Myers S, Ruppa K, Wilson L, Tahirovic Y, Lyuboslavsky P, Menaldino D
J Pharmacol Exp Ther. 2021; 379(1):41-52.
PMID: 34493631
PMC: 8626636.
DOI: 10.1124/jpet.120.000370.
NMDARs Containing NR2B Subunit Do Not Contribute to the LTP Form of Hippocampal Plasticity: In Vivo Pharmacological Evidence in Rats.
Ahnaou A, Heleven K, Biermans R, Manyakov N, Drinkenburg W
Int J Mol Sci. 2021; 22(16).
PMID: 34445376
PMC: 8395520.
DOI: 10.3390/ijms22168672.
A common mechanism allows selective targeting of GluN2B subunit-containing -methyl-D-aspartate receptors.
Schreiber J, Schepmann D, Frehland B, Thum S, Datunashvili M, Budde T
Commun Biol. 2019; 2:420.
PMID: 31754650
PMC: 6858350.
DOI: 10.1038/s42003-019-0645-6.
Mechanisms for Zinc and Proton Inhibition of the GluN1/GluN2A NMDA Receptor.
Jalali-Yazdi F, Chowdhury S, Yoshioka C, Gouaux E
Cell. 2018; 175(6):1520-1532.e15.
PMID: 30500536
PMC: 6333211.
DOI: 10.1016/j.cell.2018.10.043.
Altered Synaptic and Extrasynaptic NMDA Receptor Properties in Substantia Nigra Dopaminergic Neurons From Mice Lacking the GluN2D Subunit.
Morris P, Mishina M, Jones S
Front Cell Neurosci. 2018; 12:354.
PMID: 30364232
PMC: 6193106.
DOI: 10.3389/fncel.2018.00354.
Structure, function, and allosteric modulation of NMDA receptors.
Hansen K, Yi F, Perszyk R, Furukawa H, Wollmuth L, Gibb A
J Gen Physiol. 2018; 150(8):1081-1105.
PMID: 30037851
PMC: 6080888.
DOI: 10.1085/jgp.201812032.
Systematic review of the pharmacological agents that have been tested against spreading depolarizations.
Klass A, Sanchez-Porras R, Santos E
J Cereb Blood Flow Metab. 2018; 38(7):1149-1179.
PMID: 29673289
PMC: 6434447.
DOI: 10.1177/0271678X18771440.
Properties of Triheteromeric -Methyl-d-Aspartate Receptors Containing Two Distinct GluN1 Isoforms.
Yi F, Zachariassen L, Dorsett K, Hansen K
Mol Pharmacol. 2018; 93(5):453-467.
PMID: 29483146
PMC: 5878673.
DOI: 10.1124/mol.117.111427.
NMDA Receptors in the Central Nervous System.
Hansen K, Yi F, Perszyk R, Menniti F, Traynelis S
Methods Mol Biol. 2017; 1677:1-80.
PMID: 28986865
PMC: 7325486.
DOI: 10.1007/978-1-4939-7321-7_1.
Mechanism and properties of positive allosteric modulation of N-methyl-d-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives.
Sapkota K, Irvine M, Fang G, Burnell E, Bannister N, Volianskis A
Neuropharmacology. 2017; 125:64-79.
PMID: 28709671
PMC: 5623084.
DOI: 10.1016/j.neuropharm.2017.07.007.
The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models.
Khlestova E, Johnson J, Krystal J, Lisman J
J Neurosci. 2016; 36(44):11151-11157.
PMID: 27807157
PMC: 5148234.
DOI: 10.1523/JNEUROSCI.1203-16.2016.
A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.
Tabakoff B, Ren W, Vanderlinden L, Snell L, Matheson C, Wang Z
Eur J Pharmacol. 2016; 784:1-14.
PMID: 27158117
PMC: 5024723.
DOI: 10.1016/j.ejphar.2016.05.006.